These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25468596)

  • 1. The corneal pocket assay.
    Ziche M; Morbidelli L
    Methods Mol Biol; 2015; 1214():15-28. PubMed ID: 25468596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The corneal pocket assay.
    Ziche M; Morbidelli L
    Methods Mol Biol; 2009; 467():319-29. PubMed ID: 19301681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studying Angiogenesis in the Rabbit Corneal Pocket Assay.
    Morbidelli L; Ciccone V; Ziche M
    Methods Mol Biol; 2021; 2206():89-101. PubMed ID: 32754813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Rabbit Corneal Pocket Assay.
    Morbidelli L; Ziche M
    Methods Mol Biol; 2016; 1430():299-310. PubMed ID: 27172962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracking adult neovascularization during ischemia and inflammation using Vegfr2-LacZ reporter mice.
    Heidenreich R; Murayama T; Silver M; Essl C; Asahara T; Rocken M; Breier G
    J Vasc Res; 2008; 45(5):437-44. PubMed ID: 18418002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mouse cornea micropocket angiogenesis assay.
    Rogers MS; Birsner AE; D'Amato RJ
    Nat Protoc; 2007; 2(10):2545-50. PubMed ID: 17947997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corneal assay for angiogenesis.
    Ziche M
    Methods Mol Med; 2001; 46():131-42. PubMed ID: 21340917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic mouse models of corneal neovascularization: new perspectives for angiogenesis research.
    Kather JN; Kroll J
    Invest Ophthalmol Vis Sci; 2014 Nov; 55(11):7637-51. PubMed ID: 25425566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current methods of anti-angiogenic influence on newly formed corneal vessels].
    Vestn Oftalmol; 2013; 129(3):98-101. PubMed ID: 23879033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency.
    Joussen AM; Germann T; Kirchhof B
    Graefes Arch Clin Exp Ophthalmol; 1999 Dec; 237(12):952-61. PubMed ID: 10654163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model.
    Mirabelli P; Peebo BB; Xeroudaki M; Koulikovska M; Lagali N
    Exp Eye Res; 2014 Aug; 125():118-27. PubMed ID: 24933712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue Plasminogen Activator as an Antiangiogenic Agent in Experimental Corneal Neovascularization in Rabbits.
    Arai KI; Yasukawa T; Kato A; Kubota A; Usui H; Takase N; Kuwayama S; Ogura Y
    Ophthalmic Res; 2018; 59(3):170-175. PubMed ID: 29533953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New corneal neovascularization model in rabbits for angiogenesis research.
    Campos-Mollo E; Pérez-Santonja JJ; Lledó-Riquelme M; Ortega Pastor E; Alió JL
    Ophthalmic Res; 2011; 45(3):135-41. PubMed ID: 20847576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization.
    Zhang Z; Ma JX; Gao G; Li C; Luo L; Zhang M; Yang W; Jiang A; Kuang W; Xu L; Chen J; Liu Z
    Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4062-71. PubMed ID: 16249481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).
    Azar DT
    Trans Am Ophthalmol Soc; 2006; 104():264-302. PubMed ID: 17471348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules.
    Dueñas Z; Torner L; Corbacho AM; Ochoa A; Gutiérrez-Ospina G; López-Barrera F; Barrios FA; Berger P; Martínez de la Escalera G; Clapp C
    Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2498-505. PubMed ID: 10509642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of corneal neovascularization with plasmid pigment epithelium-derived factor (p-PEDF) delivered by synthetic amphiphile INTeraction-18 (SAINT-18) vector in an experimental model of rat corneal angiogenesis.
    Kuo CN; Yang LC; Yang CT; Lai CH; Chen MF; Chen CY; Chen CH; Wu PC; Kou HK; Chen YJ; Hung CH; Tsai CB
    Exp Eye Res; 2009 Nov; 89(5):678-85. PubMed ID: 19596319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model of angiogenesis in the mouse cornea.
    Kenyon BM; Voest EE; Chen CC; Flynn E; Folkman J; D'Amato RJ
    Invest Ophthalmol Vis Sci; 1996 Jul; 37(8):1625-32. PubMed ID: 8675406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.
    Kadar T; Amir A; Cohen L; Cohen M; Sahar R; Gutman H; Horwitz V; Dachir S
    Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
    Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
    Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.